Regeneron Pharmaceuticals Inc (REGN)’s Dupixent Has Multi-Billion-Dollar Potential: Polen Capital

Florida-based investment manager Polen Capital is bullish on Regeneron Pharmaceuticals Inc (NASDAQ:REGN), a New York-based biotech company with six FDA-approved medicines and ...

Keep Reading →